Alisertib
Alisertib (pronounced: al-i-ser-tib) is a small molecule inhibitor of the Aurora kinase A enzyme, which is involved in cell division. It is currently being studied for its potential use in the treatment of various types of cancer.
Etymology
The name "Alisertib" is derived from the Latin word "alis", meaning "wing", and the Greek word "sertib", meaning "to inhibit". This reflects the drug's mechanism of action, which is to inhibit the "wings" (spindle fibers) of dividing cells.
Pharmacology
Alisertib works by inhibiting the activity of Aurora kinase A, an enzyme that plays a crucial role in cell division. By blocking this enzyme, Alisertib can prevent cancer cells from dividing and growing.
Clinical Trials
Alisertib has been tested in several clinical trials for various types of cancer, including breast cancer, ovarian cancer, and lung cancer. While results have been promising, further research is needed to determine the drug's efficacy and safety profile.
Side Effects
Common side effects of Alisertib include fatigue, nausea, and hair loss. More serious side effects can include low blood cell counts, which can lead to an increased risk of infection.
Related Terms
External links
- Medical encyclopedia article on Alisertib
- Wikipedia's article - Alisertib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski